IP Library › Granted Patent US 10,233,262
Granted Patent B2
US 10,233,262 · App. 15/038,423 · Granted Mar 19, 2019

Glycan analysis

Inventors: Dennis Blank (Biberach, DE); Manfred Wuhrer (Voorschoten, NL); Karli Robert Reiding (The Hague, NL)
Assignee: ACADEMISCH ZIEKENHUIS LEIDEN
C08B37/0006G01N21/6428H01J49/0027H01J49/164H01J49/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,233,262
App. No.
15/038,423
Granted
Mar 19, 2019
Kind
B2
Abstract

The present invention concerns methods of derivatizing sialic acids which may be present on glycan moieties. This can be of use in determining the glycosylation profiles of, for example, glycoproteins and glycolipids and the use of such methods in clinical analysis as well as biological development and control.

Claims (27)

1. A method for derivatizing sialic acid residues present on glycan moieties by linkage specific alkyl esterification and lactone formation, the method comprising:

reacting a biological sample or glycan preparation with an alcohol solution comprising a reagent comprising at least one carbodiimide(s) and at least one triazole or ethyl 2-cyano-2-(hydroxyimino)acetate (Oxyma pure), in order to derivatize any sialic acid residues present on glycan moieties present in the biological sample or glycan preparation.

2. The method according to claim 1 wherein acetylation of sialic acids is preserved with derivatization.

3. The method according to claim 1 , wherein said at least one carbodiimide is N,N′-Dicyclohexylcarbodiimide (DCC), or 1 ethyl-3-(3-dimethyl amminopropyl) carbodiimide (EDC).

4. The method according to claim 1 , wherein said triazole is hydroxybenzotriazole (HOBt).

5. The method according to claim 4 wherein hydroxybenzotriazole (HOBt) is in a hydrated form.

6. The method according to claim 1 , wherein the reagent is a mixture, selected from the group consisting of DCC with HOBt, DCC with oxyma pure, EDC with HOBt and EDC with oxyma pure.

7. The method according to claim 1 , wherein the alcohol is methanol, ethanol, (iso)propanol or butanol.

8. The method according to claim 7 wherein the alcohol is ethanol.

9. The method according to claim 1 , wherein the method is carried out under acidic or neutral conditions.

10. The method according to claim 9 wherein the method is carried out in acidic conditions.

11. The method according to claim 10 wherein such acidic conditions are provided by the addition of 0.1%-0.4% trifluoracetic acid (TFA).

12. The method according to claim 1 , wherein the method is carried out on pure or impure samples.

13. The method according to claim 12 wherein the impure sample is a biological sample.

14. The method according to claim 13 wherein the biological sample is a sample of plasma, immunoglobulin or fibrinogen which has been subjected to an enzymatic digestion.

15. The method according to claim 1 , wherein the glycan moiety prior to or after derivatization is labelled with a radio or non-radioactive label isotope, or fluorescent or luminescent label.

16. The method according to claim 15 wherein the derivatized and labelled sialylated glycans are purified following derivatization and labelling by hydrophilic interaction chromatography (HILIC), porous graphitized carbon solid phase extraction (PGC-SPE), cationic exchange resins, liquid-liquid extraction or a mixture of the foregoing.

17. The method according to claim 1 , wherein the derivatized sialylated glycans are purified following derivatization by hydrophilic interaction chromatography (HILIC) porous graphitized carbon solid phase extraction (PGC-SPE), cationic exchange resins, liquid-liquid extraction or a mixture of the foregoing.

18. The method according to claim 1 , further comprising analysing the derivatized sialic acid residues present on the glycan moieties, by way of a suitable separation and detection of differentially linked sialic acids.

19. The method according to claim 18 wherein the derivatized sialic acid residues present on the glycan moieties are analysed by a mass spectrometric technique.

20. The method according to claim 19 wherein the mass spectrometric technique is MALDI-TOF analysis.

21. The method according to claim 20 wherein the derivatized sample is subjected to a recrystallisation step prior to the sample being analysed by MALDI-TOF.

22. The method according to claim 1 wherein the method detects and/or determines sialic acid acetylation and/or sialylation.

23. The method according to claim 1 wherein the sialic acid residues are linked to any monosaccharide.

24. The method according to claim 1 wherein the sialic acid residues are linked to either another sialic acid containing moiety, a hexose or N-acetylhexosamine.

25. A method of derivatizing sialic acid residues present on glycan moieties by linkage specific alkyl esterification and lactone formation, the method comprising:

enzymatically treating a biological sample or glycan preparation in order to release glycan moieties present within the sample; and directly reacting the treated biological sample or glycan preparation with an alcohol solution comprising a reagent comprising at least one carbodiimide(s) and at least one triazole or ethyl 2-cyano-2-(hydroxyimino)acetate (Oxyma pure), in order to derivatize any sialic acid residues present on glycan moieties present in the biological sample or glycan preparation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2018
From: BLANK, DENNIS; WUHRER, MANFRED; REIDING, KARLI ROBERT
To: ACADEMISCH ZIEKENHUIS LEIDEN
Reel/Frame 047556/0049 →
Priority Claims (1)
GB 1320571.1 · Nov 21, 2013 · national
Continuity (1)
Related Publication 20160289346A1 · Oct 6, 2016